Introduction
The transfer of the gene encoding coagulation factor VIII (FVIII) is currently studied as a novel therapeutic approach for the treatment of hemophilia A. [1] [2] [3] Hemophilia is regarded as an attractive candidate for gene therapy for several reasons. (1) Hemophilia is a monogeneic recessive disorder. (2) Therapeutic or prophylactic protein substitution is an effective treatment with a wide therapeutic window (1.5 to 4100% of normal). (3) There is a variety of potential target cells since closely regulated or site-specific expression will probably not be required. For these reasons, gene transfer of FVIII has been among the first clinical gene therapy trials for nonmalignant diseases.
Recent preclinical gene transfer studies evaluated the delivery of FVIII genes in vivo by adenoviral, [4] [5] [6] [7] [8] [9] [10] [11] adenoassociated, [12] [13] [14] [15] [16] and retroviral or lentiviral vectors. [17] [18] [19] [20] In vivo application of these vectors can indeed result in efficient transduction and transgene expression, and progress has been made to reduce vector-mediated toxicity. A major obstacle of all gene therapy protocols remains the frequent induction of inhibitory anti-FVIII immune responses.
Ex vivo approaches to hemophilia A gene therapy may have the advantage of avoiding the systemic administration of viral vectors, but have failed so far to achieve high-level FVIII expression in the plasma. Target cells used were skin fibroblasts, [21] [22] [23] bone marrow (BM) stroma cells, 24, 25 and hematopoietic progenitor cells. 26, 27 Expression of plasma FVIII was low and transient in the studies using fibroblasts and BM stroma cells. Transplanted hematopoietic progenitors did not secrete detectable amounts of plasma FVIII, although efficient transduction and mRNA expression could be demonstrated. 27 Therefore, the ability of hematopoietic cells to synthesize and/or secrete functional transgenic FVIII has been questioned. Interestingly, the transplantation of FVIII-transduced hematopoietic progenitors induced specific immune tolerance to human FVIII in immunocompetent mice. 27 This may indicate that FVIII protein was expressed in certain cells types, possibly antigenpresenting cells (APC). The current study therefore evaluates the ability of various hematopoietic cell types to synthesize and secrete functional recombinant FVIII after lentiviral transduction. In addition, we studied whether transplantation of transduced SRC (for severe immunodeficient mice repopulating cells) can give rise to differentiated hematopoietic cells that express recombinant FVIII.
Results

Generation of recombinant lentiviral FVIII vectors
To study recombinant FVIII expression, target cells were transduced with lentiviral vectors based on human immunodeficiency virus (HIV-1) containing canine Bdomain deleted FVIII (cFVIII-BDD) under the control of an internal cytomegalovirus (CMV) promoter (Figure 1 ). The number of lentiviral particles in viral supernatant was quantified by real-time PCR. Preparations of pRRL-PPT-CMV-FVIII-W-SIN contained 1 Â 10 9 to 1 Â 10 10 copies/ml (see below). To determine the number of infectious particles, 293 T cells were transduced with serial dilutions of viral supernatant. The number of vector integrations into genomic DNA was quantified by transgene-specific real-time PCR. Copy numbers of an autosomal gene, human hematopoietic cell kinase (HCK), were determined in parallel for normalization of DNA input. In a series of four experiments, the mean titer of pRRL-PPT-CMV-FVIII-W-SIN preparations ranged between 4 Â 10 7 and 4 Â 10 8 transducing units (TU) per ml (data not shown).
To improve transduction by HIV-1-derived lentiviral vectors, the HIV-1 cPPT/CTS (for central polypurine tract/ central termination sequence) was included into pRRL-CMV-FVIII-W-SIN to generate pRRL-PPT-CMV-FVIII-W-SIN ( Figure 1 ). In 293 T cells transduced with equal particle numbers of either vector, transduction was fourfold higher with the vector containing cPPT/CTS determined by quantitative PCR (Figure 2 ). Likewise, FVIII:C activity detected in cell culture supernatant was higher 24 h after transduction using pRRL-PPT-CMV-FVIII-W-SIN (250 mU/ml) compared to pRRL-CMV-FVIII-W-SIN (30 mU/ml). Based on these results, cPPT/CTS-containing vectors were used in all further experiments.
Transduction of hematopoietic cell lines
Various hematopoietic cell lines were transduced with pRRL-PPT-CMV-FVIII-W-SIN at a multiplicity of infection (MOI) of 10. After 6 days, normalized transduction rates were determined by real-time PCR from genomic DNA specific for cFVIII-BDD and HCK (Table 1) . Transduction was very efficient for most cells lines (2000-8000 vector copies per 2000 HCK copies), but was lower in the myeloid cell line Kasumi, the pre-B cell line BV-173, and the T-cell line Molt-4 (o1000). Secretion of FVIII into cell culture supernatant was assayed 6 days after transduction, because a steady-state concentration was reached at this time (data not shown). FVIII:C was detectable in several myeloid, monocytic and megakaryocytic cell line supernatants, with the highest levels obtained in the megakaryocytic line Meg-01 (Table 1) . In contrast, FVIII:C was not detected in the supernatant of transduced lymphatic cell lines. Compared to 293 T cells transduced at the same MOI, both transduction rates and FVIII:C levels were substantially lower in all hematopoietic cell lines tested. Mock-transduced cells or cells transduced with enhanced green-fluorescent protein (EGFP) did not produce detectable FVIII:C (data not shown).
To analyze transgene-specific effects, hematopoietic cell lines were also transduced with pRRL-PPT-CMV-EGFP-W-SIN encoding EGFP as a reporter gene at the same MOI. EGFP expression was subsequently quantified by flow cytometry (Figure 3a) . In lymphatic cell lines, lentiviral transduction and, accordingly, transgene expression were low. In contrast, several myeloid cell lines that were transduced efficiently, expressed both transgenes at significantly higher levels. Interestingly, marked differences between EGFP and cFVIII-BDD expression were observed among myeloid cell lines (Figure 3b ). TF-1 and Meg-01 cells were transduced with similar efficiency and expressed comparable amounts of 
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Transduction of primary hematopoietic cells
Since monocytic cell lines were able to secrete recombinant FVIII, we next transduced primary human CD14 þ monocytes from peripheral blood (PB). In initial experiments using pRRL-PPT-CMV-EGFP-W-SIN at an MOI of 20, flow cytometry revealed 70-80% EGFP-positive CD14 þ cells (data not shown). Using pRRL-PPT-CMV-FVIII-SIN at an MOI of 3, 10, and 30, a mean transduction rate of 160, 840, and 3900 vector copies per 2000 HCK copies was obtained, respectively ( Figure 4) . FVIII:C activity was detected in conditioned culture supernatant ranging between 25 and 400 mU/ml (corresponding to 1 and 20 mU/10 4 cells, respectively). The clotting factor activity closely correlated with the mean transduction rate. During short-term culture of cFVIII-BDD-trans- Factor VIII expression in hematopoietic cells A Tiede et al duced monocytes, the expression of cFVIII-BDD was detectable for up to 12 days. Expression ceased with decreasing numbers of viable cells after 8 to 10 days as monocytes with or without lentiviral transduction did not survive for more than 20 days in our cell cultures. Untransduced or EGFP-transduced monocytes did not produce detectable FVIII:C.
Adherent cell-depleted PB-derived mononuclear cells (mainly lymphocytes) were also transduced using pRRL-PPT-CMV-EGFP-W-SIN and pRRL-PPT-CMV-FVIII-W-SIN at an MOI of 20. Similar to the results obtained with lymphatic cell lines, transduction was less efficient (only up to 8% EGFP-positive by flow cytometry), and FVIII:C was not detectable in conditioned cell culture supernatant (data not shown).
Transduction of primary human CD34
þ cells and transplantation into NOD/SCID recipients Human PB-derived CD34 þ cells from two different donors were transduced with pRRL-PPT-CMV-FVIII-W-SIN in the presence or absence of recombinant fibronectin fragment CH-296 at different MOI (Table 2 ). After double transduction at an MOI of 3, the vector was detectable by PCR in B15% of the hematopoietic colonies derived from CD34 þ cells. Using an MOI of 2 Â 15 and CH-296 to improve lentiviral transduction, the vector could be detected by PCR in B50% of the colonies (Table 2) . FVIII:C was reproducibly detected at a very low level (10-20 mU/ml) in culture medium of transduced CD34 þ cells after 5 days of suspension culture in the presence of human SCF, IL-6, Flt-3L, and thrombopoietin (TPO) (five independent experiments). Untransduced CD34 þ cells did not express detectable FVIII. Human CD34 þ cells were then transduced with pRRL-PPT-CMV-FVIII-W-SIN at an MOI of 2 Â 10 in the presence of CH-296 and transplanted into sublethally irradiated NOD/SCID mice (for nonobese diabetic/severe immunodeficient mice, n¼6). At 6 weeks after transplantation, BM engraftment of human CD45 þ cells ranged between 1 and 30% as analyzed by flow cytometry (Figure 5a ). Similar results were obtained by real-time PCR specific for human HCK from total BM genomic DNA (66-1803 HCK copies from approximately 5000 BM cells, Figure 5b ). The transduction rate quantified by realtime PCR ranged between 5.8 and 2600 vector copies per 2000 HCK copies (corresponding to 1000 nucleated human cells, Figure 5c ). There was a trend towards lower engraftment at higher transduction rates that did not reach significance (Spearman correlation coefficient À0.7, two-tailed P¼0.14). Interestingly, cFVIII-BDD was not detectable by ELISA in the plasma of any NOD/ SCID mouse 6 weeks after transplantation (data not shown).
To assess whether engrafted human cells were able to secrete functional recombinant cFVIII-BDD, human CD45 þ CD33 high CD71 int monocytic cells were enriched to 495% from the BM of two mice (#5 and #6, Figure 5d ). As an internal control, human CD45 þ CD33 À CD71
À lymphatic cells were enriched to 495% in parallel. Cell numbers were stable in culture for 10 days, but rapidly declined thereafter. On day 9, cFVIII-BDD was not detectable by one-stage assay in the supernatant of lymphatic cells (o10 mU/ml, Figure 5e ). In contrast, human monocytic cells from mice #5 and #6 secreted cFVIII-BDD ranging between 10.3 and 17.7 mU/ml (or 2 and 4 mU/10 4 cells), respectively. Given the low transduction rate of human cells in these mice, FVIII production by SRC-derived monocytes seems comparable to that by PB-derived monocytes transduced ex vivo (compare vector integration and cFVIII-BDD expression for MOI¼3 in Figure 4a and b).
Discussion
This study was designed to evaluate hematopoietic cells as target cells for gene transfer of coagulation factor VIII in hemophilia A. It has previously been shown that retroviral transduction and transplantation of unselected BM cells does not lead to detectable expression of plasma FVIII in recipient mice. 26, 27 Because engraftment of transduced cells and expression of FVIII mRNA could be demonstrated, it seemed possible that hematopoietic cells were unable to produce recombinant FVIII due to a block in biosynthesis or secretion of this complex molecule. However, recent studies identified hepatic Kupffer cells, which are of hematopoietic origin, as major producers of FVIII in humans. 28 Therefore, we used lentiviral gene transfer that has been established as an efficient tool to transduce human CD34 þ hematopoietic progenitors including SRC. [29] [30] [31] [32] [33] Lentiviral transduction was quantified by real-time PCR and expression of recombinant FVIII was analyzed by a functional one-stage clotting assay. For this study, a CMV promoter was chosen because of its high transcriptional activity in most hematopoietic and nonhematopoietic cell types. To optimize lentiviral transduction, we introduced the HIV-1 central DNA flap (cPPT/CTS) into our vectors. 
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The addition of the cPPT/CTS sequence improved transduction and transgene expression by cFVIII-BDDencoding vectors. FVIII is considerably larger than the transgenes previously used (EGFP, b-galactosidase, factor IX). [33] [34] [35] [36] [37] In our experiments, the improvement of transduction rates by cPPT/CTS was stronger in cFVIII-BDD-encoding vectors compared to EGFP-encoding vectors, indicating that cPPT/CTS might be particularly important with larger transgenes.
We first transduced different hematopoietic cell lines with FVIII-encoding vectors. In all cell lines tested, expression of cFVIII-BDD was less effective than in 293 T cells that were transduced with higher efficacy. However, a megakaryocytic cell line and several monocytic and myeloid cell lines expressed considerable amounts of functional cFVIII-BDD. In contrast, cFVIII-BDD expression was not detected in culture supernatants from lymphatic cell lines that were transduced less efficiently. The lower transduction rate of lymphatic cell lines and primary lymphatic cells is probably because our lentiviral vectors were devoid of HIV-1 accessory proteins. 38 To analyze transgene-specific effects, we compared expression of cFVIII-BDD and EGFP following transduction with otherwise similar lentiviral constructs. Differences in the efficacy of FVIII secretion were found in cell lines with comparable transduction rates and EGFP expression. These differences are probably due to cellular cofactors that may be relevant for biosynthesis or secretion of specific transgenic proteins such as the von Willebrand factor for FVIII in Meg-01 cells.
We also found that PB-derived mature monocytes are able to secrete recombinant FVIII upon lentiviral transduction. This parallels the ability of mononuclear phagocytes to produce many secretory proteins such as enzymes, coagulation factors and complement components. However, monocytic cells frequently leave the blood vessels and become resident tissue macrophages. Recombinant FVIII secreted by these cells may not reach the blood stream.
Lymphocytes and CD34 þ hematopoietic progenitors poorly produced functional recombinant FVIII in vitro although efficient transduction was achieved in CD34 þ cells. Therefore, it seems likely that FVIII biosynthesis or secretion is blocked in these cells. In addition, ineffective ectopic expression of FVIII in hematopoietic stem and progenitor cells might interfere with their engraftment and differentiation capability. Indeed, the transduction rate of SRC by FVIII-encoding vectors was lower compared to previous experiments using EGFPencoding lentiviral vectors under similar conditions. 33 Furthermore, we observed that engraftment decreased with increasing transduction rates, which was not the case in experiments with EGFP-transduced SRC. 33 Therefore, FVIII expression in CD34 þ cells may be detrimental to engraftment. Selective expression of FVIII in differentiated hematopoietic cells, preferably monocytes or megakaryocytes, may be obtained by lineage-specific regulatory elements in future experiments.
In this study, similar to previous work, 26, 27 transplantation of transduced hematopoietic progenitors did not result in detectable FVIII expression in the plasma. However, human monocytic cells derived from BM of transplanted mice were observed to secrete functional FVIII ex vivo. This indicates that FVIII expression is not prevented by a block in biosynthesis or secretion in such cells. More likely, the amount of recombinant FVIII 27 Monocytes are professional APC and may also develop into different types of dendritic cells. Presentation of peptide antigens on these cells will induce specific T cell tolerance by mechanisms of clonal deletion and/or anergy. Only in the context of inflammation, when APC receive additional 'danger' signals, Major histocompatibility complex (MHC) presentation of peptides is accompanied by costimulatory signals (B7, CD40 ligand) that promote activation, proliferation and differentiation of specific T cells. 39 'Danger' may be signaled to APC via pattern recognition receptors that bind to substances of bacterial or viral origin. In the context of in vivo gene therapy, this may explain why transduction of APC by viral particles can provoke immune responses. 40 In contrast, ex vivo transduction of hematopoietic progenitors developing into APC after transplantation, may allow for the presentation of neo-antigenic peptides in the absence of danger signals. Therefore, central and/or peripheral tolerance may be achieved. Tolerance induction has also been demonstrated as a result of nonmyeloablative transplantation of gene-modified HSC in mice and non-human primates. 41, 42 In summary, our data show for the first time that gene transfer into CD34 þ progenitor cells may direct differentiated hematopoietic cells such as monocytes to secrete a recombinant nonhematopoietic gene product. This principle may be generally applicable in the field of experimental gene therapy and may allow the correction of genetic defects for many secreted proteins. However, transgene-specific effects on the engraftment of transduced HSC may have to be considered. For hemophilia A, recombinant FVIII expression by hematopoietic cells may not achieve sufficient FVIII plasma activity under the conditions currently used, but may induce immune tolerance against FVIII. In the future, induction of immune tolerance as well as biosynthesis and secretion of transgenic proteins at clinically relevant levels could be achieved by improving gene transfer into HSC and their subsequent transplantation. This strategy may allow to evaluate a potentially long-lasting, curative correction of a wide range of genetic disorders.
Materials and methods
Plasmids
Cloning of canine (c)FVIII has been described previously. 43 A 4.8 kb cDNA encoding cFVIII-BDD was provided by D Lillicrap (Kingston, ON, Canada). A lentiviral three-plasmid system based on the transgenic plasmid pRRL-CMV-EGFP-SIN, the packaging construct pCMVD8.9.3, and the envelope plasmid pMD.G was used. [44] [45] [46] pRRL-CMV-EGFP-SIN was modified as follows ( Figure 1) . (1) The woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was introduced downstream of EGFP using an EcoRI site. ( 2) The HIV-1 cPPT/CTS was inserted as a NarI fragment upstream of the CMV promoter into a ClaI site. (3) The EGFP cDNA was replaced with the cFVIII-BDD cDNA using the MluI and BstBI sites to give pRRL-CMV-FVIII-W-SIN and pRRL-PPT-CMV-FVIII-W-SIN.
Lentivirus production
Lentiviral particles were produced by transient transfection of 293 T cells as described. 33 Briefly, 72 h before transfection, 3 Â 10 6 cells were seeded in 180 cm 2 culture flasks coated with poly-L-lysine (Sigma, Deisenhofen, Germany). Cells were transfected using the calcium chloride method with 60 mg transgenic plasmid, 40 mg pCMVD8.9.3, and 20 mg pMD.G per flask in the presence of 25 mM chloroquine. After 10-12 h, the DNA precipitate was removed, cells were washed with PBS and incubated in Dulbeco's Minimal Eagle's Medium (DMEM)/10% FCS containing 10 mM sodium butyrate for 10 h. Lentiviral particles were then collected in serum-free X-VIVO/10 medium (Bio-Whittaker, Heidelberg, Germany, 12 mL per flask) every 12 h for 2 days. Supernatants were pooled and concentrated at 8000 g, 101C for 12-14 h. Pellets were resuspended in X-VIVO/10 supplemented with 1% human serum albumin (HSA), and aliquots were stored at À801C.
Determination of vector titers
Titers of EGFP-encoding vectors are given in TU/ml and were determined as previously described. 47 For titration of cFVIII-BDD-encoding vectors, 293 T cells were seeded in 24-well culture dishes at 1 Â 10 5 cells/well. Transduction was performed with serial dilutions (10 À3 to 10
À7
) of virus in DMEM/FCS containing 8 mg/ml polybrene and 200 mM desoxynucleotides (dNTP) for 12 h. After washing and incubation in DMEM/FCS at 371C for 48 h, cells were harvested and genomic DNA was extracted using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany). The number of integrated provirus copies was determined by real-time PCR.
Real-time PCR
Reagents, equipment and procedures of real-time PCR (TaqMan PCR) have been described previously. 47, 48 For the quantitation of virions in concentrated vector preparations, we used PCR primers and a probe specific for the U5 strong-stop cDNA as described. 47 To quantify provirus integration, genomic DNA from transduced cells was amplified using cFVIII-specific primers (forward 5 0 -GAT CTC CGA GAG GCC ACA G; reverse 5 0 -TTG AGA CTG GTG GGT TTT GAG) and a FAM/TAMRAlabeled TaqMan probe spanning the B-domain deletion of cFVIII-BDD (5 0 -AGC AAT AGA AAG AAA CAA GGG CCC TTG). For normalization of cell input, we quantified endogenous HCK copy numbers using PCR primers and a VIC/TAMRA-labeled TaqMan probe as described. 49 Standard curves were generated using dilutions of plasmid DNA (2 Â 10 1 to 2 Â 10 7 copies per reaction) with R 
Primary hematopoietic cells
Human PB was collected from healthy donors after informed consent. PBMNC were isolated by Ficoll gradient centrifugation. Monocytes were enriched from PBMNC using anti-CD14 microbeads (Miltenyi, Bergisch-Gladbach, Germany) and were cultured in RPMI 1640 containing 10% heat-inactivated FCS and 5 mM Lglutamine. Human PB-derived CD34 þ cells obtained from two healthy donors were enriched to 498% using anti-CD34 microbeads (CliniMACS, Miltenyi) as described. 33 CD34 þ cells were cultured either in X-VIVO/ 10 containing 1% HSA or in RPMI 1640 containing 10% heat-inactivated FCS and 5 mM L-glutamine. As indicated, media were supplemented with human recombinant granulocyte colony-stimulating factor (G-CSF, 20 ng/ml, Amgen, Munich, Germany), granulocyte macrophage colony-stimulating factor (GM-CSF, 20 ng/ ml, Novartis, Basel, Switzerland), stem cell factor (SCF, 100 ng/ml, Amgen), thrombopoietin (TPO, 100 ng/ml, R&D Systems, Wiesenbaden-Nordenstadt, Germany), erythropoietin (Epo, 2.5 U/ml, Roche Diagnostics), Flt-3 ligand (Flt-3L, 100 ng/ml, Genzyme, Alzenau, Germany), IL-3 (10 ng/ml, Roche Diagnostics), and IL-6 (20 ng/ml, Roche Diagnostics).
Transduction procedures
Hematopoietic cells were seeded at 0.5 to 2 Â 10 6 per ml in serum-free X-VIVO/10 supplemented with 1% HSA, 200 mM dNTP and 4 mg/ml protamine sulfate in 24-well dishes coated with CH-296 (Retronectin; Takara Shuzo, Japan) as indicated. Dilutions of vector stocks were added to give the indicated MOI (ie 293 T TU per cell). For mock transduction, an equivalent volume of medium was added. After spinocculation at 1000 g, 321C for 90 min, cells were incubated at 371C overnight, washed in PBS and suspended in culture media as indicated. In some experiments, cells were transduced twice, that is after spinocculation and incubation for 4-6 h, fresh viral supernatant was added and spinocculation was repeated before cells were incubated overnight.
FVIII assays
To quantify FVIII activity (FVIII:C), samples from culture supernatants were centrifuged at 13 000 rpm in an Eppendorf microcentrifuge for 5 min to remove cells and cellular debris. The supernatant was diluted 1:5 and 1:10 in diethylbarbiturate acetate buffer, pH 7.6. 100 ml of the dilution were incubated with 100 ml FVIII-depleted human plasma and 100 ml Pathromtin reagent (Dade Behring, Marburg, Germany) at 371C for 6 min. Then, 100 ml 25 mM calcium chloride (371C) were added and the clotting time was measured using a Schnitger & Gross coagulometer. Reference curves were established with human recombinant B-domain deleted FVIII (Refacto Lab Standard, 9 U/ml, Wyeth Pharma, Mü nster, Germany) diluted in DMEM/FCS or RPMI/FCS. cFVIII-BDD antigen was quantified using the Asserachrome ELISA obtained from Roche Diagnostics (Mannheim, Germany) This assay was performed according to the manufacturer's instructions, except that human recombinant FVIII-BDD (Refacto) was used to establish reference curves. The sensitivity of cFVIII-BDD detection was corresponding to a one-stage assay activity of 80 mU/ml.
Methylcellulose assays
Human CD34
þ cells (1 Â 10 3 ) were suspended in 1 ml methylcellulose-based media (MethoCult, StemCell Technologies, Vancouver, BC, Canada) supplemented with human IL-3, SCF, GM-CSF, G-CSF, and Epo. On day 14, individual colonies were picked under microscopic control, resuspended in 200 ml deionized water, vortexed vigorously and incubated at 951C for 15 min. After spinning at 10 000 rpm for 5 min, supernatants were subjected to PCR analysis (cFVIII-BDD and HCK primers as given above; triplicate assays for each sample using 21.5 ml supernatant per 50 ml reaction).
NOD/SCID xenotransplantation
Human PB-derived CD34 þ cells were transduced in the presence of CH-296, TPO, SCF, IL-6 and Flt-3L. Untransduced control cells were cultured in parallel under identical conditions. NOD/SCID mice were sublethally irradiated (2 Gy), and received (i) no cells, (ii) 1.4 Â 10 6 untransduced cells, or (iii) 2.4 Â 10 6 transduced cells. The difference in the number of transplanted cells between groups (ii) and (iii) was due to a loss of cells during preparation. After 6 weeks, BM was harvested from killed mice and engraftment of human hematopoietic cells was studied by flow cytometry using PE-labeled mouse anti-human CD45 (Beckman Coulter, Hamburg, Germany) and PerCP-labeled rat anti-mouse CD45 (BD Bioscience, Heidelberg, Germany). Transduction efficiency was assessed by quantitiative real-time PCR specific for human HCK and cFVIII-BDD from BM genomic DNA as described above. For enrichment of human monocytic and lymphatic cells, BM cells were stained with APC-labeled mouse anti-human CD45 (Beckman Coulter), PE-labeled mouse anti-human CD71 (BD Bioscience), and FITC-labeled mouse antihuman CD33 (BD Bioscience). Cell sorting was performed on a MoFlo high-speed sorter (Cytomation, Fort Collins, CO, USA ) were cultured in 100 ml RPMI 1640 supplemented with 20% heat-inactivated FCS and GM-CSF for monocytes.
Statistics
Repeated measurements are given as mean7standard deviation (s.d.). Regression curves for double-logarithmic and half-logarithmic figures were generated using GraphPad Prism (log y¼a þ b log x and y¼a þ b log x, respectively; weighted for 1/y 2 ). Engraftment and transduction rates in mice were correlated by nonparametric Spearman's rank correlation.
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